A Randomized, Multi-Center, Double-Blind, Cross-Over Study Comparing the Efficacy and Safety of Dex-Methylphenidate Extended Release 20 mg Versus Placebo at the 0.5 Hour Timepoint (Post-Dose) in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.

Trial Profile

A Randomized, Multi-Center, Double-Blind, Cross-Over Study Comparing the Efficacy and Safety of Dex-Methylphenidate Extended Release 20 mg Versus Placebo at the 0.5 Hour Timepoint (Post-Dose) in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.

Completed
Phase of Trial: Phase IV

Latest Information Update: 26 Apr 2012

At a glance

  • Drugs Dexmethylphenidate (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 01 Aug 2008 Results have been published in CNS drugs. Primary and secondary endpoints met.
    • 22 Dec 2007 Status changed from recruiting to completed.
    • 19 Dec 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top